Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Ertugliflozin Monotherapy in T2DM
NCT01958671Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2013
- Primary completion
- Jul 2016
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ertugliflozin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Oct 2013; status: completed.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01958671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01958671.